Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.

Start Date01 Dec 2025

Sponsor / Collaborator

Hartford Hospital

[+1]

NCT06956014

/ Not yet recruitingPhase 3

Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Patients With Chronic Low Back Pain

The aim of the trial is to prove the efficacy and safety of VER-01 corresponding to 22.5 mg or 32.5 mg THC compared to placebo in patients with chronic low back pain (CLBP) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Start Date01 Nov 2025

Sponsor / Collaborator

Vertanical GmbH

NCT06731894

/ Not yet recruitingPhase 2IIT

A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy

This phase II trials evaluates how well different types of phytocannabinoids (cannabidiol [CBD] versus tetrahydrocannabinol [THC] and CBD formulation [THC:CBD]) work to reduce chronic chemotherapy-induced peripheral neuropathy among breast and colon cancer survivors. Chemotherapy induced peripheral neuropathy is a set of symptoms that includes pain, tingling, numbness and motor weakness caused by certain types of chemotherapy treatment. Phytocannabinoids are compounds made by the cannabis plant, such as THC and CBD, that have been found to be an effective treatment for chronic pain. Phytocannabinoids may be effective in reducing chronic chemotherapy-induced peripheral neuropathy symptoms in patients treated for breast or colon cancer.

Start Date27 Oct 2025

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

100 Clinical Results associated with Dronabinol

100 Translational Medicine associated with Dronabinol

100 Patents (Medical) associated with Dronabinol

15,809

Literatures (Medical) associated with Dronabinol

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

The impact of cannabis use on local anesthetic dosing during hair restoration surgery: a case report, proposed mechanisms, and clinical recommendations

Review

Author: Keene, Sharon A. ; Gupta, Aditya K. ; Talukder, Mesbah

Cannabis use has increased significantly in the last decade. This article presents a case where a patient needed more local anesthetic (LA) than usual to induce effective anesthesia during hair transplant surgery. The reason cannabis users often need more LA is poorly understood. One possibility is that cannabis withdrawal effect makes patients more sensitive to pain and stress. Additionally, vasodilatory property of cannabis may speed up LA clearance from the application site. The interactions of two major cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), with cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), and transient receptor potential vanilloid 1 (TRPV1) receptors are also complex. Furthermore, CBD and THC function as cytochrome P450 enzyme inhibitors potentially impacting systemic metabolism. When planning to administer LA during hair restoration surgery in cannabis users, clinicians should obtain a detailed history of prior consumption (type of cannabis, frequency, dosage). Preoperative planning should consider the anticipated duration of surgery and calculate the maximum safe LA dose to avoid the risk of toxicity. Also, patients should be carefully monitored for vital signs during surgery. If a patient requires frequent re-injection to remain pain free, the surgeon may need to re-assess the surgical plan to avoid toxicity.

01 Nov 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Simultaneous analysis of four endocannabinoids and endocannabinoid congeners together with delta-9 tetrahydrocannabinol and related metabolites in dried blood spots

Article

Author: Richeval, Camille ; Gish, Alexandr ; Wiart, Jean-François ; Gaulier, Jean-Michel ; Allorge, Delphine

In the medical field, the endocannabinoid system is both a difficult and hot topic for scientific and media reasons (cannabis, cannabidiol, etc.). Due to their instability and low concentrations in blood and physicochemical properties, the complexity of endocannabinoid assay is previously reported in different matrices. This study aims to report a LC-MS/MS method for the simultaneous quantification of four endocannabinoids and endocannabinoid congeners: N-arachidonoylethanolamide (anandamide or AEA), 2-arachidonoylglycerol/1-arachidonoylglycerol (2-AG/1-AG), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), together with Δ9-tetrahydrocannabinol (THC) and its main metabolites [11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) and 11-hydroxy- Δ9-tetrahydrocannabinol (11-OH THC] in Dried Blood Spot (DBS). This validated method reported LLOQs of 0.1 µg/L for AEA, 0.5 µg/L for THC and 11-OH THC, and 1 µg/L for OEA, PEA, 2AG and THC-COOH. The method demonstrated intra- and interassay accuracy and precision of less than 20 % for the LLOQ, and less than 15 % for the other calibration points. In particular, the stability carried out in this study demonstrated the practical applicability of DBS for the measurement of endocannabinoids in the whole blood. Therefore, we propose this method as a tool for basic and clinical research to support the growing interest of the scientific community in the endocannabinoid system.

01 Nov 2025·CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Unwinding the Threads of Mesoporous Silica Nanoparticles as Cutting-edge for the Management of Inflammation: An Updated Review

Article

Author: Sharma, Neelam ; Singh, Sukhbir ; Arora, Sandeep ; Dhiman, Priya ; Kishore, Ladli ; Gulia, Ritu

Background::

Inflammation serves as a protective response to combat cellular and tissue damage. There is currently a wide array of synthetic and traditional therapies available for the treatment of inflammatory diseases. However, it is necessary to create a drug delivery system based on nanotechnology that can improve the solubility, permeability, and bioavailability of current treatments. Mesoporous silica nanoparticles (MSNPs) are inorganic materials known for their organised porous interiors, high pore volumes, substantial surface area, exceptional selectivity, permeability, low refractive index, and customisable pore sizes.

Objective::

This review offers concise insights into the progression of the pathophysiology of inflammation, as well as the inducers, mediators, and effectors that are involved in the inflammatory pathway. This study focuses on the growing significance of MSNPs in the treatment of neuroinflammation, inflammatory bowel disease, arthritic inflammation, lung inflammation, and wound healing applications. This review also presents the latest information on the crucial role of MSNPs in delivering herbal medicines for the treatment of inflammation.

Methods::

A comprehensive literature search was conducted for this aim, utilising the Google Scholar, PubMed, and ScienceDirect databases. A systematic review was undertaken utilising scholarly articles published in peer-reviewed journals from 2000 to 2024.

Results::

The inflammatory mediators involved in the pathophysiology of inflammation include platelet-activating factor, lipoxygenase, cyclooxygenase, Interferon-α, interleukin-6, interleukin- 1β, matrix metalloproteinases, inducible nitric oxide synthase, nuclear factor-κB, prostaglandins, nitric oxide, and phospholipase A2. MSNPs have the potential to be used in the treatment of neuroinflammation, inflammatory bowel disease, arthritic inflammation, lung inflammation, and wound healing. The investigation of the MSNPs of plant-based compounds such as berberine, tetrahydrocannabinol, curcumin, and resveratrol has shown successful results in recent years for the purpose of managing inflammation.

Conclusion::

This review demonstrates that MSNPs have a strong potential to play a positive role in delivering synthetic and plant-based therapies for the treatment of inflammatory illnesses.

504

News (Medical) associated with Dronabinol

26 Jun 2025

·www.globenewswire.com

Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations

New Study Provides Insight into the Bioavailability of Medical Cannabis Formulations for Therapeutic TreatmentNEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, today announced the publication of a scientific study. This new research focuses on comparing the bioavailability of different cannabinoid formulations, taking a step forward in our understanding of medical cannabis. The study aimed to assess the pharmacokinetic parameters and relative bioavailability of two D9-tetrahydrocannabinol: cannabidiol (THC:CBD) formulations. (A) An orally administered: Tilray THC:CBD extract and (B) an oromucosally administered nabiximols formulation. This pilot crossover study counterbalanced (1) 1 mL of orally administered Tilray THC:CBD extract (10 mg/mL each of THC and CBD) and (2) oromucosally administered nabiximols (four sprays of 2.7 mg THC and 2.5 mg CBD per spray, for a total dose of 10.8 mg THC and 10 mg CBD). Blood samples were obtained pre-dose and at 16 post-dose time points over 24 hours. Pharmacokinetic parameters were calculated for THC, 11-hydroxy-tetrahydrocannabinol (11-OH-THC), and CBD. Conducted with twelve healthy volunteers (6 male, 6 female) under fasting conditions, the results revealed that the Cmax for THC and CBD was significantly higher for the Tilray THC:CBD extract compared to nabiximols and neither Tmax nor AUC was significantly different for the two treatments. Interestingly, the Cmax for nabiximols was significantly higher in males compared to females. Under both treatment conditions, THC and CBD were undetectable 24 hours post-dose, and 11-OH-THC was markedly reduced from its peak. Notably, no serious adverse events were reported. This pilot study shows that oral administration of Tilray THC:CBD extract formulation achieved higher THC and CBD concentrations within a shorter timeframe compared to the oromucosal delivery of nabiximols. These findings may have significant implications for clinical populations using these formulations therapeutically. José Tempero, Tilray’s Medical Director, remarked, "By advancing our understanding of cannabinoid pharmacokinetics, we are better equipped to develop formulations that can significantly enhance therapeutic outcomes. We extend our heartfelt thanks to our partners in this study for their invaluable contributions and collaboration." Denise Faltishchek, Chief Strategy Officer and Head of International at Tilray, added, "This pioneering research exemplifies our commitment to advancing the science of medical cannabis. By deepening our understanding of cannabinoid pharmacokinetics, we strive to enhance the therapeutic potential of our products, ultimately improving the quality of life for patients globally. Our goal is to continue driving innovation and providing patients with safe, effective, consistent and reliable medical cannabis solutions for patients around the world." Tilray Medical is a leading provider of EU-GMP certified and pharmaceutical-grade medical cannabis products, having supplied over 20 countries with a comprehensive portfolio of THC and CBD products. Tilray has supported medical trials globally, across Europe, Canada, the United States, Australia, and Latin America, studying the efficacy of medical cannabis as a treatment for indications including pediatric epilepsy, refractory pediatric epilepsy, cancer-induced nausea and vomiting, HIV, essential tremor, breast cancer disorders, post-traumatic stress disorder, and alcohol use disorders. About Tilray Medical Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis, having supplied to patients, physicians, hospitals, pharmacies, researchers, and governments in over 20 countries and across five continents. For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand. About Tilray Brands Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, New Zealand and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages. For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms. Forward-Looking Statements Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws. For further information: Media: news@tilray.comInvestor Relations: investors@tilray.com

Clinical Result

05 Jun 2025

·pharma.economictimes.indiatimes.com

Surge in new opioids and designer drugs threatens Europe, EU drug agency warns

Madrid: Massive shipments of previously unknown recreational designer drugs and potent new opioids are threatening Europe, while traffic of cocaine and cannabis is worsening, according to the European Union Drugs Agency's annual report published on Thursday. Seizures of synthetic cathinones - stimulants chemically akin to the active ingredient in khat, a plant widely consumed in East Africa and the Arabian Peninsula - reached 37 metric tons in 2023, primarily imported from India. Seven new cathinones were identified last year, suggesting their growing prevalence. The report also warned of new synthetic opioids, particularly nitazenes, which it said posed "severe poisoning" risks. Nitazenes can be orders of magnitude stronger than heroin - or even fentanyl - and have been linked by U.S. and British authorities to increases in overdose deaths. The report - which compiled data from the 27 EU member states plus Norway and Turkey - stressed the need for improved monitoring and alert systems, as well as better preparedness and cross-sector collaboration to combat drug-related crime and public health risks. Meanwhile, cannabis remained Europe's most consumed illicit drug, with increasingly potent products complicating health risk assessments. The average tetrahydrocannabinol (THC) content in cannabis resin has doubled over the past decade, the report said. In 2024, authorities detected 18 new varieties of semi-synthetic cannabinoids such as hexahydrocannabinol (HHC), which in many countries can be sold legally because those molecules are often not explicitly banned. Cocaine use was also rising, as shown by record seizures of 419 tons in 2023. Major ports in Belgium, Spain, and the Netherlands were key entry points, the report said. (Reporting by David Latona; Editing by Inti Landauro and Edwina Gibbs)

05 Jun 2025

·www.einpresswire.com

Bud & Mary’s Expands Sleep Relief Options for Iowa Medical Cannabis Patients with Launch of NUO Sleep Tablets

Medical Cannabis Sleep Solution is Formulated with Minor Cannabinoids and Backed by Research At Bud & Mary’s, we’re deeply invested in understanding how cannabinoids interact with the brain and body, especially when it comes to improving individuals’ sleep quality.” — Lucas Nelson, Group President of Bud & Mary’s DES MOINES, IA, UNITED STATES, June 5, 2025 / EINPresswire.com / -- DES MOINES, Iowa (June 5, 2025) — Iowa medical cannabis patients can now access Bud & Mary’s NUO Sleep Tablets , a science-driven oral product that is the first of its kind in the state formulated with a blend of THC, CBD, and the minor cannabinoid CBN. Discreet, portable and precisely dosed, NUO Sleep Tablets are crafted to ease patients into a peaceful night and help them wake feeling refreshed. Scored for titrating doses, NUO Sleep Tablets serve medical cannabis patients seeking a smoke-free non-combustible, orally administered format that helps set the mood for sleep. The tablets -- free from sugar, preservatives, dyes, alcohols and artificial ingredients -- demonstrate Bud & Mary’s ongoing commitment to creating trusted, research -backed cannabis therapies. “At Bud & Mary’s, we’re deeply invested in understanding how cannabinoids interact with the brain and body, especially when it comes to improving individuals’ sleep quality” said Lucas Nelson, Group President of Bud & Mary’s. “NUO Sleep Tablets reflect that commitment, combining precise dosing with emerging research on minor cannabinoids such as CBN. It is the next step in our work to offer Iowa patients reliable, non-combustible therapies that are grounded in science and tailored for real-world needs.” Bud & Mary’s is one of the only U.S. cannabis license holders with a DEA Schedule 1 researcher license, enabling federally authorized cannabis research. With an ISO 17025-accredited analytical laboratory, cGMP/GACP-certified production, and multiple active clinical studies, the company sets a national standard for cannabis innovation, scientific rigor, and product safety. “Sleep is one of our most fundamental biological needs, yet so many people struggle to get consistent, uninterrupted sleep,” said Dr. Duncan Mackie, Director of Pharmacology & Experimental Therapeutics at Bud & Mary’s. “Research has shown that disturbed or insufficient sleep can affect mood, cognitive performance, and overall physical health. Now, NUO Sleep Tablets offer Iowa patients a reliable, science-backed option to assist them in obtaining a peaceful, uninterrupted night’s sleep.” As part of Bud & Mary’s dedication to researching how cannabis-based therapeutics can transform lives, the company is currently conducting a sleep-focused clinical trial with the University of Iowa, studying the effects of a patented cannabinoid-based therapeutic intradermal gel designed to improve sleep among individuals aged 50 or older with diagnosed sleep disturbances. Iowa medical cannabis patients with valid prescriptions can find NUO Sleep Tablets in licensed dispensaries across the state in 10-count and 30-count bottles. Patients can locate Iowa dispensaries that offer NUO Sleep Tablets in the store locator at this link. Product images are available at this link. Iowans seeking more information on obtaining a medical cannabis card can visit BudMary.com/IA/GetACard. For more information or to schedule an interview, please contact Irene Ancheta at 310-804-5493 or irene@themaverickpr.com. Bud & Mary’s: Crafted for You, Powered by Science. At Bud & Mary’s, we take a science-driven approach to crafting premium cannabis products designed for every individual. From our best-selling BATCH vape cartridges to our innovative water-soluble TheMyx powder and wellness-focused brands Become and NUO, every product is developed with care, precision, and an unwavering commitment to quality. Locally grown and rigorously tested, Bud & Mary’s products meet the highest standards of safety, consistency, and excellence. As we’ve pushed boundaries of cannabis innovation and expanded our offerings into Colorado, Michigan, Iowa, and Missouri, we’ve remained true to our family-owned and operated roots and people-focused values. For more information, visit BudMary.com. Continue the conversation on Facebook, Instagram, X, LinkedIn and TikTok. # # # Irene Ancheta Maverick Public Relations +1 310-804-5493 email us here Visit us on social media: LinkedIn Instagram Facebook TikTok X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Dronabinol

External Link

KEGG	Wiki	ATC	Drug Bank
D00306	Dronabinol	A04AD10	DB00470

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anorexia	United States	Alkem Laboratories Ltd.	31 May 1985
Nausea	United States	Alkem Laboratories Ltd.	31 May 1985
Vomiting	United States	Alkem Laboratories Ltd.	31 May 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chemotherapy-induced nausea and vomiting	NDA/BLA	Canada	Tetra Bio-Pharma, Inc.	01 May 2023
Sleep Apnea, Obstructive	Phase 3	United States	RespireRx Pharmaceuticals, Inc.	01 Feb 2023
Decrease in appetite	Phase 3	Europe	Solvay SA	15 Feb 2007
Alzheimer Disease	Phase 2	United States	Unimed Pharmaceutical, Inc.	29 Jul 1996
Depressive Disorder	Phase 2	United States	Unimed Pharmaceutical, Inc.	29 Jul 1996
Parkinson Disease	Preclinical	Canada	Pike Therapeutics, Inc.	01 Nov 2024
Cognition Disorders	Preclinical	Israel	Therapix Biosciences Ltd /Non-Pain Assets/	13 May 2018
Cachexia	Discovery	South America	Avicanna, Inc.	14 Feb 2022
Multiple Sclerosis	Discovery	United States	Unimed Pharmaceutical, Inc.	14 Aug 2003
Pain	Discovery	United States	Unimed Pharmaceutical, Inc.	13 Oct 1999

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05820685 (DOPE, CTgov)	Phase 4	Pain	484	Standard of Care (Standard of Care)	xmbhjturyk(rmlpmsyysa) = vfwiknnqvw obndsukygy (qhgpwgwpdr, nbrswuayub - hcervzasoq) View more	-	11 Jun 2025
				Standard of Care+Dronabinol (Standard of Care + Dronabinol)	xmbhjturyk(rmlpmsyysa) = ywaitotjbn obndsukygy (qhgpwgwpdr, drjhvdbfma - cmqjtyythm) View more
NCT04130633 (CTgov)	Phase 1	-	33	Placebo	rixgdvpvtp(hpwvxidies) = zxyhlvzovx ausuhkjgev (bmrdrriwdr, 16.9) View more	-	22 May 2025
NCT02792257 (THC-AD, CTgov)	Phase 2	Alzheimer Disease \| Agitation	84	Dronabinol (Dronabinol)	ecnosyshcd(cwqsbeqxtl) = rkjdcvukut wjiosjubjp (qnozabvxig, 4.12) View more	-	09 May 2025
				Placebo (Placebo)	ecnosyshcd(cwqsbeqxtl) = kypdewfbil wjiosjubjp (qnozabvxig, 4.18) View more
NCT02817698 (CTgov)	Early Phase 1	Smoking \| Marijuana Abuse \| Unspecified drug dependence	25	cannabis	gqllszvuuw(fqvbaoqiie) = gooctlqfsg xgarwtigwj (lyzkbbxnkc, sjmaivatdz - woyzthapjy) View more	-	12 Dec 2024
NTIASD1 (Company_Website) Manual	Phase 1/2	Autism Spectrum Disorder	14	NTI164	fitxjsltxz(oflvqadltz) = qpnnqawysz qebrztibcd (jraixlhyuu )	Positive	01 Dec 2024
NCT03804840 (AIS, CTgov)	Early Phase 1	Thrombocytopenia 1	72	Placebo (Placebo)	wtylkywzrf(qrsvawzgnk) = skcduhnwqk vumgcmmats (lqrdjpvrsi, .07) View more	-	19 Sep 2024
				Dronabinol (7.5 mg THC)	wtylkywzrf(qrsvawzgnk) = kotbkacykj vumgcmmats (lqrdjpvrsi, .09) View more
NCT03809546 (IDT, CTgov)	Early Phase 1	Thrombocytopenia 1	60	dextrose (Placebo)	ihsczaegcg(dlqleoaeek) = grfzggjxln vwilklexvd (vvfsfzygmv, 0.047) View more	-	03 Jul 2024
				Dronabinol (7.5 mg THC)	ihsczaegcg(dlqleoaeek) = vvvfdtlled vwilklexvd (vvfsfzygmv, 0.07) View more
ACTRN12619000037101 (ASCO2024)	Phase 2	Advanced cancer	144	10mg/ml THC:10mg/ml CBD combination oil	sbnpocjjsg(lluakvsgxe) = 26/69 and 12/72 txaohmsuzr (vbgfgnvfbv ) View more	Negative	24 May 2024
				Placebo
NCT05192239 (CTgov)	Early Phase 1	-	17	Placebo (Placebo)	veiwkzuhgc(jozisggink) = mgjfzwdqcd mioikvnkpf (zgqffryswv, 0.3711208) View more	-	22 Apr 2024
				THC 5 (10 mg THC)	veiwkzuhgc(jozisggink) = tbzgtptxnz mioikvnkpf (zgqffryswv, 0.358376) View more
S22.010 (AAN2024)	Not Applicable	Acute migraine	92	6% THC	krraocanze(pdixafekce) = daqjacktpp vjzbmrkfrl (ieerggdmso ) View more	Positive	09 Apr 2024
				6% THC/11% CBD mix	krraocanze(pdixafekce) = inredzseef vjzbmrkfrl (ieerggdmso ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis